Hypofractionated radiation therapy, which is delivered in larger doses over a shorter time period than conventional RT, can result in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research presented at the American Society for Radiation Oncology’s annual meeting.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
